There were more than 100,000 reported deaths from opioid overdoses in 2021, according to the Centers for Disease Control and Prevention. Methadone treatment remains one of the most reliable means of treating opioid use disorder, with success rates reportedly ranging from 60%–90% for patients who stick with the long-term regimen. Adherence, though, remains a challenge.
In a novel randomised clinical trial published in JAMA Network Open, senior author Ted J. Kaptchuk at Beth Israel Deaconess Medical Center (BIDMC), lead author Annabelle Belcher, PhD, of the University of Maryland School of Medicine, and colleagues tested whether using open-label placebo could increase the efficacy of methadone treatment for people undergoing care for opioid use disorder. The researchers found that participants who knowingly received placebo pills in addition to standard-of-care methadone treatment were significantly more likely to remain in treatment than participants who received methadone treatment alone. Participants who received placebo pills also reported better sleep quality.
“The clinical implications of our intervention have great potential impact, as retention in treatment is a serious challenge for the field of addiction medicine,” said Belcher. “We’ve demonstrated it’s feasible to administer a placebo in addition to standard-of-care methadone in a community-based opioid treatment setting without adding a significant burden to clinic procedures, and the low-cost, low-risk nature of this intervention could provide an appealing strategy to target early methadone treatment adherence.”
It has long been assumed that deception or concealment is necessary for placebo effects – “tricking” a patient to believe an inert pill contains the active medication. But, a growing body of evidence in randomised controlled trials with irritable bowel syndrome, chronic low back pain, cancer-related fatigue, migraine and other conditions has demonstrated no such deception is necessary for placebo treatment to alleviate symptoms. Additionally, conditioning study participants to placebos by having them pair the placebo with an active medication – thereby potentially associating the placebo with relief in symptoms that may be caused by the active drug – has also been shown to treat symptoms of insomnia, ADHD, post-surgical pain, and more.
For this two-arm, open-label, single-blind randomized controlled trial, 131 newly enrolled adult patients seeking treatment for moderate-to-severe opioid use disorder (OUD) at an academically affiliated community opioid treatment program were recruited. All participants were informed of the possible benefits of open-label placebo and conditioning. The research team also described the neurobiological and psychological mechanisms of placebo effects and conditioning in lay terms and in a routine, supportive setting. Then, participants were randomized either to receive treatment-as-usual or treatment-as-usual plus a conditioned open-label placebo (microcrystalline cellulose pills).
While the participants were aware that they were taking a placebo pill, the clinical addiction care team was unaware as to which participants were in the treatment-as-usual or treatment-plus-placebo groups and the trial altogether to avoid any unconscious differential treatment. All participants were seen at weeks two, four, eight, and 12 after the initial enrollment and underwent the same outcome assessments. Those in the placebo group were not provided with any additional information about placebos or the rationale of the study beyond what was provided at the baseline meeting.
Researchers assessed patients’ 90-day methadone dose, treatment retention, self-reported drug use, withdrawal, craving, quality of life, and sleep quality. Contrary to the researchers’ expectations, the conditioned open-label placebo had no impact on the 90-day methadone dose. However, participants treated with an open-label placebo were significantly more likely to remain in treatment; 78% of the placebo-treated group stayed with the program compared to 61% of the methadone-only group. The placebo group also reported better sleep quality. No statistically significant differences were found in any other outcome measures.
“Implementing a unique combination of two methods to harness the placebo effect – open-label placebo and pharmacological conditioning – we found a significant difference in the group’s 90-day retention rates, demonstrating that placebo treatment can provide valuable benefits and still adhere to ethical norms of informed consent,” said Kaptchuk, director of the Program in Placebo Studies and the Therapeutic Encounter at BIDMC and professor of medicine at Harvard Medical School. “Previous assumptions that placebo treatment needs concealment or deception to ‘work’ are not true. Additionally, there is growing evidence that open-label placebo demonstrates similar neurotransmitter engagement to double-blind and deceptive placebos. It is important to note that a patient-clinician relationship is an important component of open-label placebo.”
